Zoledronic acid is effective in the treatment of prostate cancer patients with bone metastases

Clinical Prostate Cancer

Volumn 1, Issue 1, 2002, Pages 12-13

  Maung, Kavita ^a   Higano, Celestia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; HYPERMAGNESEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0041381334     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1540-0352(11)70118-4     Document Type: Article

References (8)

1. Campa JA III, Payne R. The management of intractable bone pain: a clinician's perspective. Semin Nucl Med 1992; 22:3-10.
2. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996; 14:2552-2559.
3. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88:1082-1090.
4. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558-567.
5. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semi Oncol 2001; 28:35-44.
6. Lee MV, Fong EM, Singer FR, et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61:2602-2608.
7. Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol 2001; 28:11-16.
8. Saad F, Gleason D, Murray R, et al. Zoledronic acid significantly reduces fractures in patients with hormone-refractory prostate cancer metastatic to bone. J Urol 2002; 167 (suppl):175 (Abstract #703).